The majority of CML patients can be successfully managed with tyrosine kinase inhibitors (TKIs), and will not need allogeneic hemopoietic cell transplantation. Allogeneic transplantation remains ...

before transplantation and the overall survival (OS) of patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). The median follow-up time among the patients was 19.7 months ...

Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia? Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with ...

[Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation].

in allogeneic hematopoietic stem cell transplantation (allo-HSCT), highlighting the role of the recipient's circadian rhythms. The team was led by Prof. Zhan Cheng from the University of Science ...

Rubin Family Endowed Chair , Fred Hutch Milton B. Rubin Family Endowed Chair Fred Hutch Dr. Rainer Storb is one of the pioneers who established allogeneic, or donor, blood stem cell transplantation as ...

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing ... allograft and standard allogeneic hematopoietic cell transplantation, it's composed of ...